Chad Oh
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard D. May, Gregory P. Geba and Nestor A. MolfinoEdward Piper*MedImmune Ltd, CambridgeChristopher Brightling#Institute of Lung Health, University of Leicester, LeicesterRobert Niven¶University of Manchester and University Hospital of South Manchester, Manchester, UKChad Oh+MedImmune, LLC, Gaithersburg, MDRaffaella Faggioni§MedImmune, LLC, Hayward, CA, USAKwai Poon*MedImmune Ltd, CambridgeDewei She+MedImmune, LLC, Gaithersburg, MDChris Kell*MedImmune Ltd, CambridgeRichard D. May*MedImmune Ltd, CambridgeGregory P. Geba+MedImmune, LLC, Gaithersburg, MDNestor A. Molfino+MedImmune, LLC, Gaithersburg, MD
- Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard May, Gregory Geba and Nestor MolfinoEdward Piper1Clinical Development, MedImmune, Gaithersburg, MD, United StatesChristopher Brightling2Institute of Lung Health, University of Leicester, Leicester, United KingdomRobert Niven3University Hospital of South Manchester, University of Manchester, Manchester, United KingdomChad Oh1Clinical Development, MedImmune, Gaithersburg, MD, United StatesRaffaella Faggioni1Clinical Development, MedImmune, Gaithersburg, MD, United StatesKwai Poon1Clinical Development, MedImmune, Gaithersburg, MD, United StatesDewei She1Clinical Development, MedImmune, Gaithersburg, MD, United StatesChris Kell1Clinical Development, MedImmune, Gaithersburg, MD, United StatesRichard May1Clinical Development, MedImmune, Gaithersburg, MD, United StatesGregory Geba4Formerly with Clinical Development, MedImmune, Gaithersburg, MD, United StatesNestor Molfino1Clinical Development, MedImmune, Gaithersburg, MD, United States
- A phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard D May, Gregory P. Geba and Nestor A MolfinoArticle | Published in 2012 in European Respiratory JournalEdward PiperChristopher BrightlingRobert NivenChad OhRaffaella FaggioniKwai PoonDewei SheChris KellRichard D MayGregory P. GebaNestor A Molfino
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.